EMP3 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant EMP3.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND

Application
| WB, IHC |
|---|---|
| Primary Accession | P54852 |
| Other Accession | BC009718 |
| Reactivity | Human |
| Host | mouse |
| Clonality | Monoclonal |
| Isotype | IgG1 Kappa |
| Clone Names | 3D4 |
| Calculated MW | 18429 Da |
| Gene ID | 2014 |
|---|---|
| Other Names | Epithelial membrane protein 3, EMP-3, Hematopoietic neural membrane protein 1, HNMP-1, Protein YMP, EMP3, YMP |
| Target/Specificity | EMP3 (AAH09718, 1 a.a. ~ 163 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Dilution | WB~~1:500~1000 IHC~~1:100~500 |
| Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
| Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Precautions | EMP3 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations. Zhou W, et al. J Korean Med Sci, 2009 Feb. PMID 19270820.EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma. Fumoto S, et al. Cancer Lett, 2009 Feb 8. PMID 18823699.DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas. Kunitz A, et al. Brain Pathol, 2007 Oct. PMID 17610521.EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q. Li KK, et al. Int J Cancer, 2007 Feb 15. PMID 17187361.Altered expression of CLC, DSG3, EMP3, S100A2, and SLPI in corneal epithelium from keratoconus patients. Nielsen K, et al. Cornea, 2005 Aug. PMID 16015083.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.





Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.





